The mechanism of action of IgG in primary immunodeficiency (PI) disease has not been fully elucidated. It is known that Privigen provides patients with a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasma agents and their toxins.
The mechanism of action for IgG therapy is complex and not fully understood. However, its success in treating CIDP—an inflammatory neuropathy with an underlying autoimmune basis—is largely attributed to its immunomodulatory effects.24
A more precise mechanism of action regarding just how IgG therapy exerts its immunomodulatory effects is still being explored, but proposed mechanisms that may play a role include24:
The mechanism of action of IgG in chronic immune thrombocytopenic purpura (ITP) is complex and not fully understood. However, the success of treating chronic ITP with IgG has been attributed to the competitive inhibition of Fc receptors on phagocytic cells.23,25
Continuing research indicates that other mechanisms may also contribute to thrombocytopenia, including22:
Although IVIg has been used to treat chronic ITP, the mechanism of action is still unclear. Further research will be needed to better understand how IVIg works in chronic ITP.22